Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
61,044,940
-
Share change
-
+3,613,317
-
Total reported value
-
$1,123,360,083
-
Put/Call ratio
-
401%
-
Price per share
-
$18.37
-
Number of holders
-
142
-
Value change
-
+$60,029,572
-
Number of buys
-
63
-
Number of sells
-
89
Institutional Holders of DICERNA PHARMACEUTICALS INC - COM (DRNA) as of Q1 2020
As of 31 Mar 2020,
DICERNA PHARMACEUTICALS INC - COM (DRNA) was held by
142 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
61,044,940 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock Inc., Bain Capital Life Sciences Investors, LLC, WELLINGTON MANAGEMENT GROUP LLP, EcoR1 Capital, LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, UBS Group AG, CITADEL ADVISORS LLC, and EAGLE ASSET MANAGEMENT INC.
This page lists
142
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.